2022
DOI: 10.1200/go.21.00355
|View full text |Cite
|
Sign up to set email alerts
|

Cost Effectiveness of Bevacizumab Plus Chemotherapy for the Treatment of Advanced and Metastatic Cervical Cancer in India—A Model-Based Economic Analysis

Abstract: PURPOSE Patients with advanced and metastatic cervical cancer have a poor prognosis with a 1-year survival rate of 10%-15%. Recently, an antiangiogenic humanized monoclonal antibody bevacizumab has shown to improve the survival of these patients. This study was designed to assess the cost effectiveness of incorporating bevacizumab with standard chemotherapy for the treatment of patients with advanced and metastatic cervical cancer in India. METHODS Using a disaggregated societal perspective and lifetime horizo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 40 publications
0
2
0
Order By: Relevance
“…The current market price for crizotinib and ceritinib is a poor value for public money for a LMIC like India. The health benefits (QALYs) from crizotinib (2.73) and ceritinib (3.34) are significantly higher as compared with other molecules like sorafenib for hepatocellular carcinoma (0.5), 47 temozolomide (1.45) 25 and bevacizumab for metastatic cervical cancer (0.13), 48 and CDK4/6i (1.6) for breast cancer. 26 Hence, we recommend nearly 81% reduction in market price of crizotinib to make it a cost-effective treatment option to be included in India's publicly financed health insurance scheme.…”
Section: Discussionmentioning
confidence: 99%
“…The current market price for crizotinib and ceritinib is a poor value for public money for a LMIC like India. The health benefits (QALYs) from crizotinib (2.73) and ceritinib (3.34) are significantly higher as compared with other molecules like sorafenib for hepatocellular carcinoma (0.5), 47 temozolomide (1.45) 25 and bevacizumab for metastatic cervical cancer (0.13), 48 and CDK4/6i (1.6) for breast cancer. 26 Hence, we recommend nearly 81% reduction in market price of crizotinib to make it a cost-effective treatment option to be included in India's publicly financed health insurance scheme.…”
Section: Discussionmentioning
confidence: 99%
“…The fourth important implication of our study is generation of unit OOPE estimates, stratified by various clinical characteristics. These can be used along with health system cost database (39), to undertake oncology specific health technology assessments (40)(41)(42).…”
Section: Overall Summary Of Findingsmentioning
confidence: 99%